Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Opioid Dependence, Methadone Withdrawal Syndrome
Interventions
Lofexidine HCl
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence
Interventions
lofexidine administration in subjects seeking buprenorphine dose reduction
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Opioid-Use Disorder
Interventions
Placebo, TRV734, Oxycodone
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal

NCT00980044
Conditions
Substance Withdrawal Syndrome
Interventions
Tramadol, Placebo
Drug
Lead sponsor
Michelle Lofwall
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Terminated Phase 1 Interventional Accepts healthy volunteers

Pioglitazone to Treat Opioid Withdrawal Symptoms

NCT01517165
Conditions
Opioid-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Opioid-Related Disorders
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania
Conditions
Opioid-Related Disorders
Interventions
Morphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

NCT00661674
Conditions
Substance-Related Disorders
Interventions
Palonosetron, Hydroxyzine, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Conditions
Heroin Dependence
Interventions
Buspirone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
25 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions
Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
McKeesport, Pennsylvania
Conditions
Withdrawal Symptoms
Interventions
Oxycodone/Naltrexone Capsules, Oxycodone, Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Opioid-Related Disorders
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Opioid-Related Disorders
Interventions
Tramadol, Naloxone, Morphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Innovative Intervention for OUD Treatment

NCT04325659
Conditions
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
Interventions
Bridge Device, Lofexidine, Placebo, Sham Bridge Device
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Rancho Mirage, California • Orlando, Florida • Pinellas Park, Florida + 3 more
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Conditions
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
Interventions
Buspirone, Lofexidine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Osteoarthritis of the Knee
Interventions
NKTR-181, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers

NCT01006707
Conditions
Substance-Related Disorders
Interventions
Ondansetron
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Conditions
Opioid Use Disorder, Pregnancy Related, Pregnancy, High Risk, Pregnancy Complications, Buprenorphine Withdrawal
Interventions
Buprenorphine Transdermal Matrix Patch, Sham patch
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Opioid Use Disorder
Interventions
sphenopalatine ganglion block
Procedure
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
22 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York